申请人:Astra Aktiebolag
公开号:US05885985A1
公开(公告)日:1999-03-23
Guanidine derivatives of formula I ##STR1## wherein R.sup.8 represents hydrogen, halogen, alkyl C1 to 6, nitro, trifluoromethyl, thioalkyl C1 to 6, hydroxy, alkoxy C1 to 6, or a group selected from --NR.sup.4 R.sup.5, --O(CH.sub.2).sub.p Q, --(CH.sub.2).sub.m OQ, --(CH.sub.2).sub.m NR.sup.1 R.sup.2, --O(CH.sub.2).sub.m NR.sup.1 R.sup.2, --NHCO(CH.sub.2).sub.m NH(CH.sub.2).sub.n Q or --(CH.sub.2).sub.p CONR.sup.1 R.sup.2, or R.sup.8 represents the group A--CO--B; R.sup.9 represents hydrogen, halogen, alkyl C1 to 6, nitro or trifluoromethyl; and R.sup.1, R.sup.2, R.sup.4, R.sup.5, n, m, p, Q, A, B, and W are as defined in the specification, are described together with processes for their manufacture and compositions containing them. Compounds of formula I are useful in therapy.
公式I的胍基衍生物##STR1##其中R.sup.8代表氢、卤素、烷基C1至6、硝基、三氟甲基、硫代烷基C1至6、羟基、烷氧基C1至6,或者从--NR.sup.4 R.sup.5、--O(CH.sub.2).sub.p Q、--(CH.sub.2).sub.m OQ、--(CH.sub.2).sub.m NR.sup.1 R.sup.2、--O(CH.sub.2).sub.m NR.sup.1 R.sup.2、--NHCO(CH.sub.2).sub.m NH(CH.sub.2).sub.n Q或--(CH.sub.2).sub.p CONR.sup.1 R.sup.2中选择的基团; 或者R.sup.8代表基团A--CO--B; R.sup.9代表氢、卤素、烷基C1至6、硝基或三氟甲基; 而R.sup.1、R.sup.2、R.sup.4、R.sup.5、n、m、p、Q、A、B和W如规范中所定义的,描述了它们的制造过程和含有它们的组合物。公式I的化合物在治疗中是有用的。